- Imperial Innovations Group has led a £22m funding round for PsiOxus Therapeutics, alongside Invesco Perpetual, and together with new investors SR One and Lundbeckfond Ventures.

PsiOxus Therapeutics, based in Oxfordshire, is a development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer, wasting diseases and other unmet clinical needs.

PsiOxus will use the funds to advance the clinical development of ColoAd1, a highly potent broad-spectrum anti-cancer therapeutic capable of destroying tumour cells at minute concentrations.

A series of phase I and phase II clinical trials for the treatment of colorectal cancer and other forms of solid cancer will be initiated.

At 8:46am: [LON:IVO] Ivory & Sime Optimum share price was +14p at 300.5p

Story provided by